A $680 million merger just blew up in a ‘surprise’ and experts say it’s a sign of pain to come for cannabis dealmaking


MedMen

MedMen terminated its $682 million merger with PharmaCann on Tuesday, in a move one analyst called ‘surprising.’
The merger’s cancellation points to a challenging dealmaking environment in the cannabis industry, as the sector has declined close to 50% in the past few months.
Business Insider spoke to lawyers, bankers, and analysts who work with cannabis companies about what this means for the industry.
Click here for more BI Prime stories and subscribe to our weekly cannabis newsletter, Cultivated.

It’s been a tough week for publicly traded cannabis companies, capping off a difficult few months for the sector.

In a surprise move on Tuesday, MedMen said it was pulling out of its proposed all-stock merger with PharmaCann. The merger, which was first announced in October of last year, would have created one of the largest US cannabis companies, and was valued at $682 million when it was announced.

Slumping share prices and consistent headwinds in the cannabis industry — namely, fear over illnesses caused by THC vapes and the slowing progress of marijuana legalization in the US — have made for a challenging dealmaking environment, according to bankers, analysts, and lawyers working with cannabis companies that Business Insider spoke with. In the last 6 months, the Horizons Marijuana Life Sciences Index ETF, a fund that tracks cannabis stocks in the US and Canada, has slipped close to 50%.

“The initial wave of investors that went after this market has been tapped out or exhausted,” Marc Hauser, the vice chair of law firm Reed Smith’s cannabis team told Business Insider in an interview. “Companies are having a much harder time raising capital than just twelve months ago.”

Read more: Here are the top bankers raising money, putting together deals, and raking in millions in the global cannabis industry

For his part, MedMen CEO Adam Bierman cited the challenging capital markets environment for cannabis companies, and the need to change up strategies as the reasons for the deal’s termination. The company also pushed out its CFO, Michael Kramer, and replaced him with Zeeshan Hyder.

It’s MedMen’s third CFO inside of a year. Business Insider reported on the departure of MedMen’s chief marketing officer, David Dancer, in September.

Vivien Azer, an analyst at the investment bank Cowen, called the deal’s failure a “surprise” after it cleared a Department of Justice antitrust review a month ago and MedMen put out an “optimistic” statement about the deal’s prospects.

MedMen …read more


Source:: Business Insider

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *